In today’s session Alnylam Pharmaceuticals, Inc. (ALNY) registered an unusually high (165) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious ALNY increase. With 165 contracts traded and 154 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: ALNY161021C00070000 closed last at: $3.3 or 32.7% down. The stock increased 0.50% or $0.34 during the last trading session, hitting $68.57. About 560,922 shares traded hands or 3.39% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 9.48% since March 2, 2016 and is uptrending. It has outperformed by 0.24% the S&P500.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 9 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Alnylam Pharmaceuticals has been the topic of 19 analyst reports since August 7, 2015 according to StockzIntelligence Inc. JP Morgan maintained it with “Overweight” rating and $83 target price in Friday, August 5 report. The firm has “Outperform” rating given on Friday, August 28 by JMP Securities. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by FBR Capital on Tuesday, August 11. The rating was initiated by Jefferies on Friday, October 23 with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Wednesday, January 20 by Credit Suisse. JP Morgan downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Friday, August 7 to “Neutral” rating. The rating was upgraded by JP Morgan on Friday, March 11 to “Overweight”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Overweight” rating by Piper Jaffray on Monday, August 31. The company was maintained on Tuesday, May 3 by Leerink Swann. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, August 2.
Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio fall, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Deutsche Bank Ag holds 0.02% or 392,751 shares in its portfolio. Numeric Investors Limited Liability Company accumulated 0.01% or 11,400 shares. Citigroup holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 80,876 shares. Morgan Stanley reported 875,104 shares or 0.02% of all its holdings. Henderson Gp Public Ltd Company, a United Kingdom-based fund reported 10,138 shares. Kcg Holdings Inc last reported 0.02% of its portfolio in the stock. Teachers Retirement Of The State Of Kentucky last reported 0.13% of its portfolio in the stock. Ls Advsr Ltd Liability holds 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1,548 shares. Manufacturers Life Insurance The has 0% invested in the company for 2,931 shares. Winfield Associate Inc accumulated 20 shares or 0% of the stock. Moreover, Voya Inv Management Ltd Co has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 31,416 shares. Teacher Retirement Sys Of Texas accumulated 5,444 shares or 0% of the stock. Aviva Pcl last reported 0.02% of its portfolio in the stock. Employees Retirement Association Of Colorado has 0.01% invested in the company for 17,829 shares. Marshall Wace Llp has invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Insider Transactions: Since April 19, 2016, the stock had 0 insider purchases, and 2 sales for $3.98 million net activity. Another trade for 30,151 shares valued at $1.95 million was sold by MARAGANORE JOHN.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $5.92 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.